NCT00212108 - A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

March 31, 2007

Study Completion Date

January 31, 2009

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

celecoxib, gefitinib

The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.

Trial Locations (1)

119074

National University Hospital, Singapore